Covenant Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Covenant Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,114	Closed	-$468K	–	199
2022 Q4	$468K	Hold	4,114	–	–	0.19%	93
2022 Q3	$255K	Hold	4,114	–	–	0.12%	143
2022 Q2	$328K	Hold	4,114	–	–	0.15%	129
2022 Q1	$433K	Sell	4,114 -930	-18%	-$90.6K	0.17%	115
2021 Q4	$544K	Hold	5,044	–	–	0.2%	112
2021 Q3	$553K	Hold	5,044	–	–	0.22%	102
2021 Q2	$472K	Hold	5,044	–	–	0.18%	113
2021 Q1	$464K	Hold	5,044	–	–	0.18%	115
2020 Q4	$369K	Sell	5,044 -139	-3%	-$10.3K	0.16%	127
2020 Q3	$403K	Sell	5,183 -787	-13%	-$54.1K	0.2%	119
2020 Q2	$332K	Buy	+5,970	New	+$255K	0.15%	147

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Covenant Partners's HZNP Position: Q1 2023 in Review

Covenant Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 4,114 shares — an estimated $468K sold.

Covenant Partners first reported a position in HZNP in Q2 2020 and held it in 11 quarters. The position peaked at $553K in Q3 2021. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Covenant Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Covenant Partners sold 4,114 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $468K.
Covenant Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and held it in 11 quarters.
Covenant Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $553K in Q3 2021.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Covenant Partners's 13F filing for Q1 2023, filed 19 Apr 2023.